Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.

P Sultanik, V Mallet, S Lagaye, A Casrouge, C Dorival, Y Barthe, H Fontaine, Christophe HEZODE, E Mottez, JP Bronowicki, F Carrat, I Theodorou, L Abel, E Gayat, A Fontanet, S Pol, ML Albert,

Liver Int 01/07/2015;35(7) : 1833-1844 10.1111/liv.12759. 23/01/2015

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.

D Jensen, KE Sherman, Christophe HEZODE, S Pol, S Zeuzem, V De Ledinghen, A Tran, M ElKhashab, ZH Younes, M Kugelmas, S Mauss, G Everson, V Luketic, J Vierling, L Serfaty, M Brunetto, J Heo, D Bernstein, F McPhee, D Hennicken, P Mendez, E Hughes, S Noviello,

J Hepatol. 01/07/2015;63(1) : 30-37 10.1016/j.jhep.2015.02.018. 19/02/2015

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.

Christophe HEZODE, T Asselah, KR Reddy, T Hassanein, M Berenguer, K Fleischer-Stepniewska, P Marcellin, C Hall, G Schnell, T Pilot-Matias, N Mobashery, R Redman, RA Vilchez, S Pol,

Lancet 20/06/2015;385(9986) : 2502-2509 10.1016/S0140-6736(15)60159-3. 31/03/2015

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Christophe HEZODE, GM Hirschfield, W Ghesquiere, W Sievert, M Rodriguez-Torres, SD Shafran, PJ Thuluvath, HA Tatum, I Waked, G Esmat, EJ Lawitz, VK Rustgi, S Pol, N Weis, PJ Pockros, M Bourliere, L Serfaty, JM Vierling, MW Fried, O Weiland, MR Brunetto, GT Everson, S Zeuzem, PY Kwo, M Sulkowski, N Brau, D Hernandez, F McPhee, M Wind-Rotolo, Z Liu, S Noviello, EA Hughes, PD Yin, S Schnittman,

Gut. 01/06/2015;64(6) : 948-956 10.1136/gutjnl-2014-307498 30/07/2014

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.

AJ Muir, F Poordad, J Lalezari, G Everson, GJ Dore, R Herring, A Sheikh, P Kwo, Christophe HEZODE, PJ Pockros, A Tran, J Yozviak, N Reau, A Ramji, K Stuart, AJ Thompson, J Vierling, B Freilich, J Cooper, W Ghesquiere, R Yang, F McPhee, EA Hughes, ES Swenson, PD Yin,

Java 05/05/2015;313(17) : 1736-1744 10.1001/jama.2015.3868.

Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.

C Moreno, Christophe HEZODE, P Marcellin, S Bourgeois, S Francque, D Samuel, F Zoulim, JD Grange, U Shukla, O Lenz, S Ouwerkerk-Mahadevan, B Fevery, M Peeters, M Beumont, W Jessner,

J Hepatol 01/05/2015;62(5) : 1047-1055 10.1016/j.jhep.2014.12.031 17/01/2015

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando

M Sulkowski, Christophe HEZODE, J Gerstoft, JM Vierling, J Mallolas, S Pol, M Kugelmas, A Murillo, N Weis, R Nahass, O Shibolet, L Serfaty, M Bourliere, E DeJesus, E Zuckerman, F Dutko, M Shaughnessy, P Hwang, AY Howe, J Wahl, M Robertson, E Barr, B Haber,

Lancet 21/03/2015;385(9973) : 1087-1097 10.1016/S0140-6736(14)61793-1. 11/11/2014

Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful

Isaac RUIZ, Cyrille FERAY, Jean-Michel PAWLOTSKY, Christophe HEZODE,

Liver Transpl. 01/03/2015;21(3) : 408-409 10.1002/lt.2405 20/01/2015

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

GJ Dore, E Lawitz, Christophe HEZODE, SD Shafran, A Ramji, HA Tatum, G Taliani, A Tran, MR Brunetto, S Zaltron, SI Strasser, N Weis, W Ghesquiere, SS Lee, D Larrey, S Pol, H Harley, J George, SK Fung, V De Ledinghen, P Hagens, F McPhee, D Hernandez, D Cohen, E Cooney, S Noviello, EA Hughes,

Gastroenterology 01/02/2015;148(2) : 355-366.e1 10.1053/j.gastro.2014.10.007 13/10/2014

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.

G Everson, C Cooper, Christophe HEZODE, ML Shiffman, E Yoshida, T Beltran-Jaramillo, P Andreone, S Bruno, P Ferenci, S Zeuzem, M Brunda, S Le Pogam, I Najera, J Zhou, MT Navarro, A Voulgari, NS Shulman, ES Yetzer,

Linver Int. 01/01/2015;35(1) : 108-119 10.1111/liv.12471. 12/02/2014